parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.01 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including astrocytes; strongest in hepatocytes	0.75
chemistry Open Targets	reachable by antibody	0.45
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	no papers tie it to Parkinson's yet	1.00
pathways Reactome	1 pathway; mostly other	0.30

No case: the score is under the bar. Receipt 11124

SLC38A3 in dopamine neurons, braak+0.28 (p 0.472) → -0.61 (p 0.080)receipt 11132
SLC38A3 in astrocytes, braak+0.28 (p 0.470) → -0.80 (p 0.009)receipt 11131

receipt 11132: SLC38A3 in dopamine neurons, braak

power: full sample -0.28 (p 0.265, n 18), 95% CI -0.66 to +0.22. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.25 (p 0.315, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.27 (p 0.277, n 18). could be the mix.
skeptic: leave-one-out range -0.38 to -0.19, sign flips 0; without severely affected donors -0.28 (p 0.265, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for SLC38A3 in dopamine neurons.

case closed: nothing better to follow up.

receipt 11131: SLC38A3 in astrocytes, braak

power: full sample -0.25 (p 0.310, n 18), 95% CI -0.64 to +0.24. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.18 (p 0.487, n 18). does not hold up.
composition: astrocytes share of nuclei vs axis -0.21 (p 0.413); controlling for it: -0.27 (p 0.277, n 18). could be the mix.
skeptic: leave-one-out range -0.41 to -0.15, sign flips 0; without severely affected donors -0.25 (p 0.310, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for SLC38A3 in astrocytes.

case closed: nothing better to follow up.

loading the receipts